T1	p 84 117	advanced nasopharyngeal carcinoma
T2	p 187 219	Nasopharyngeal carcinoma ( NPC )
T3	p 382 408	patients with advanced NPC
T4	p 432 551	From December 1993 to April 1999 , 284 patients with 1992 American Joint Committee on Cancer stage III to IV ( M0 ) NPC
T5	p 1845 1871	patients with advanced NPC
T6	i 25 53	concurrent chemoradiotherapy
T7	i 61 73	radiotherapy
T8	i 308 345	concurrent chemoradiotherapy ( CCRT )
T9	i 353 372	radiotherapy ( RT )
T10	i 721 733	chemotherapy
T11	i 739 748	cisplatin
T12	i 771 783	fluorouracil
T13	i 1162 1166	CCRT
T14	i 1171 1179	RT-alone
T15	i 1258 1262	CCRT
T16	i 1286 1293	RT-only
T17	i 1376 1380	CCRT
T18	i 1416 1423	RT-only
T19	i 1499 1503	CCRT
T20	i 1812 1816	CCRT
T21	i 1832 1834	RT
T22	o 139 176	overall and progression-free survival
T23	o 866 883	Survival analysis
T24	o 1141 1154	tumor relapse
T25	o 1208 1237	5-year overall survival rates
T26	o 1317 1355	5-year progression-free survival rates
T27	o 1473 1481	toxicity
T28	o 1520 1530	leukopenia
T29	o 1535 1541	emesis
T30	o 1743 1767	treatment-related deaths